Adaptin Bio APTN
OTC APTN
$6.27 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Adaptin Bio (APTN) Return on Equity [ROE] (2025)

Updated

Adaptin Bio (APTN) posted Return on Equity [ROE] of -368.37% for Q2 2025.

Analysis

Adaptin Bio (APTN) Return on Equity [ROE] (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 25.32%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 7.21%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 31.52%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 21.39%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 83.75%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -18.38%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 4.97%
10 Adaptin Bio 56.76 Mn 54.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -368.37%
API Access

Adaptin Bio Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=APTN&period=max&api_key=YOUR_API_KEY